In compliance with Regulation 33 of the SEBI LODR Regulations, 2015, the audited standalone and consolidated financial results along with the independent auditor''s report, and declaration ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sampre Nutritions' Board approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with statutory auditor N G Rao & Associates issuing an unmodified (unqualified) opinion. Full-year revenue from operations was essentially flat at Rs. 2,512.42 Lakhs versus Rs. 2,514.68 Lakhs in FY24. However, the company swung to a heavy loss, reporting a standalone loss after tax of Rs. 730.92 Lakhs (consolidated: Rs. 767.23 Lakhs) compared to a profit of Rs. 30.95 Lakhs (consolidated: Rs. 23.18 Lakhs) last year. Total expenses surged 32% to Rs. 3,266 Lakhs, driven by a sharp jump in employee costs (Rs. 1,080 vs Rs. 775 Lakhs) and other expenses (Rs. 969 vs Rs. 366 Lakhs). During the year, the company raised equity of Rs. 77.3 crores and invested heavily in a new wholly-owned subsidiary, Sampre Nutritions FZCO, while cash on hand fell to just Rs. 5.63 Lakhs.
The dramatic swing from profit to a Rs. 7+ crore loss, with expenses ballooning while revenue stayed flat, is a serious negative signal for shareholders. The equity infusion masks weak core operations, and shareholders should expect continued pressure on the stock given the operational deterioration.